要闻！电力股强势反弹：高温天气驱动电力需求 政策利好释放发展潜力

电力股强势反弹：高温天气驱动电力需求 政策利好释放发展潜力

北京 - 2024年6月15日，A股和港股电力股今日延续强势反弹，中国电力（02380）涨超5%，报3.98港元；中广核电力（01816）涨超4%，报3.45港元；华润电力（00836）涨超3%，报24.20港元；华电国际（01071）涨超2%，报5.32港元。

市场分析人士认为，电力股持续上涨主要得益于以下因素：

**1. 高温天气驱动电力需求激增。**随着夏季高温天气的到来，全国各地空调等制冷电器的使用量大幅增加，导致电力需求激增。据国家电网预测，今年夏季全国最高峰负荷将达13亿千瓦以上，同比增长5%左右。

**2. 国家政策利好电力行业发展。**近期，国家出台了一系列支持电力行业发展的政策措施，包括加大电力基础设施投资、提高电力供给质量、鼓励发展可再生能源等。这些政策措施将为电力行业发展提供强劲动力。

**3. 电力股估值处于低位。**从估值水平来看，电力股目前的估值水平相对较低，具有较高的投资吸引力。

**有分析人士指出，**随着夏季高温天气的持续，电力需求有望继续保持增长，电力股有望迎来进一步的上涨行情。此外，在国家政策的大力支持下，电力行业发展前景广阔，电力股长期投资价值值得期待。

具体来看，中国电力是香港最大的电力企业之一，拥有丰富的电力资产和良好的盈利能力。中广核电力是中国核电行业的龙头企业，拥有广阔的发展前景。华润电力是华润集团旗下的大型电力企业，拥有雄厚的实力和良好的品牌形象。华电国际是国家电网旗下的大型电力企业，拥有丰富的海外电力资产。

总体而言，电力股在近期表现强劲，有望继续保持上涨趋势。投资者可以适当关注。

**此外，**有分析人士还建议，投资者在选择电力股时，应关注以下几个方面：

• **公司经营状况：**优先选择业绩优良、盈利能力强的电力企业。
• **资产质量：**优先选择拥有优质电力资产的电力企业。
• **估值水平：**选择估值合理的电力企业，避免追涨杀跌。

在全球经济复苏和能源转型的大背景下，电力行业的发展前景广阔。投资者可以长期关注电力行业投资机会。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.